trending Market Intelligence /marketintelligence/en/news-insights/trending/WrmKv-_o1om_Vcpg34qTcQ2 content esgSubNav
In This List

Cabaletta Bio prices $66.2M Nasdaq IPO

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector


Cabaletta Bio prices $66.2M Nasdaq IPO

Cabaletta Bio Inc. priced its IPO of 6.8 million common shares at $11 apiece to raise about $66.2 million in net proceeds.

The biotechnology company granted the underwriters a 30-day option to buy up to an additional 1,020,000 common shares in the offering.

Cabaletta said its shares will trade on the Nasdaq Global Select Market under the CABA symbol beginning Oct. 25.

The transaction is expected to complete Oct. 29, subject to customary closing conditions.

Philadelphia-based Cabaletta is developing engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company previously said it plans to use the net proceeds primarily to further the clinical development of desmoglein 3 chimeric autoantibody receptor T cells, a potential therapy to counter a rare autoimmune disorder called mucosal pemphigus vulgaris.

Morgan Stanley, Cowen and Evercore ISI are acting as joint book-running managers for the offering.